Work

863P A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in pts with selected FRα -positive solid tumours: Results in the endometrial cancer (EC) cohort

Year: 2020

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.08.1002

Authors: M.C. Cristea, P. Frankel, T. Synold, D.B. Stewart, E. Wang, A. Jung, S. Wilczynski, M. Tran, G.E. Konecny, M. Eng, L. Kilpatrick, Y-J. Chen, S. Glaser, E. Han, T. Dellinger, A. Hakim, S. Lee, R.J. Morgan, L. Rodriguez, M. Wakabayashi

Institutions: City Of Hope National Medical Center, City of Hope, University of California, Los Angeles

Language: English

Topic: Endometrial and Cervical Cancer Treatments

Subfield: Obstetrics and Gynecology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, AstraZeneca, National Comprehensive Cancer Network, Eisai, PharmaMar

OpenAlex ID: W3088276265

FWCI:

Cites:

Cited by: 2

Related to: 10